UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000052478
Receipt number R000059894
Scientific Title Studies on the relationship between plasma concentrations of linezolid and its efficacy and thrombocytopenia
Date of disclosure of the study information 2023/10/13
Last modified on 2023/10/12 17:43:21

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Studies on the relationship between plasma concentrations of linezolid and its efficacy and thrombocytopenia

Acronym

Studies on the relationship between plasma concentrations of linezolid and its efficacy and thrombocytopenia

Scientific Title

Studies on the relationship between plasma concentrations of linezolid and its efficacy and thrombocytopenia

Scientific Title:Acronym

Studies on the relationship between plasma concentrations of linezolid and its efficacy and thrombocytopenia

Region

Japan


Condition

Condition

infectious disease

Classification by specialty

Infectious disease Orthopedics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Plasma concentrations of LZD are measured, and LZD dosage is adjusted based on these plasma concentrations and renal function to minimize the occurrence of LZD-induced thrombocytopenia and to ensure that treatment with LZD is continued.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Treatment efficacy (duration of LZD treatment, treatment completion rate, clinical improvement rate of infection) and incidence of adverse events (thrombocytopenia) when dose adjustment is performed based on LZD plasma concentration

Key secondary outcomes

Association of LZD plasma concentrations with LZD dose adjustment rate, treatment efficacy, and adverse event occurrence by measuring plasma concentrations


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Three to five days after the start of linezolid administration, blood should be drawn to measure plasma concentrations, and the dose should be changed (either continued at the current dose or reduced) based on the plasma concentrations obtained and renal function.
Plasma concentrations should be measured at least once a week to monitor plasma concentration trends.
Dosing should be continued until treatment of infection is completed.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients 18 years of age or older treated with LZD
Patients diagnosed with an orthopedic infection between September 1, 2023 and September 31, 2025
Patients with written consent to participate in this study

Key exclusion criteria

Patients allergic to LZD
Patients with disseminated intravascular coagulation syndrome

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Daiki
Middle name
Last name Yamaguchi

Organization

Gifu Prefectural Tajimi Hospital

Division name

pharmaceutical department

Zip code

507-8522

Address

5-161 Maehata-cho, Tajimi-shi, Gifu

TEL

0572-22-5311

Email

yamaguchi-daiki@tajimi-hospital.jp


Public contact

Name of contact person

1st name Daiki
Middle name
Last name Yamaguchi

Organization

Gifu Prefectural Tajimi Hospital

Division name

pharmaceutical department

Zip code

507-8522

Address

5-161 Maehata-cho, Tajimi-shi, Gifu

TEL

0572-22-5311

Homepage URL


Email

yamaguchi-daiki@tajimi-hospital.jp


Sponsor or person

Institute

Gifu Prefectural Tajimi Hospital

Institute

Department

Personal name



Funding Source

Organization

Gifu Prefectural Tajimi Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Gifu Pharmaceutical University

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Gifu Prefectural Tajimi Hospital

Address

5-161 Maehata-cho, Tajimi-shi, Gifu

Tel

0572-22-5311

Email

yamaguchi-daiki@tajimi-hospital.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

岐阜県立多治見病院


Other administrative information

Date of disclosure of the study information

2023 Year 10 Month 13 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2023 Year 09 Month 05 Day

Date of IRB

2023 Year 09 Month 25 Day

Anticipated trial start date

2023 Year 09 Month 25 Day

Last follow-up date

2025 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 10 Month 12 Day

Last modified on

2023 Year 10 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000059894


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name